eli lilly sues compounders for selling unauthorized tirzepatide copies finds impurity in compounded version of its weight-loss drug, warns of health risks Lilly sues four compounders over

Oxyntomodulin has been shown to reduce bodyweight and food intake in rodents and humans [11, 12] and to increase energy expenditure in people with obesity [13], via activity at both receptors

Peptide therapy has changed the lives of many people across the globe

For example, some people are more prone to folate deficiency and may need to supplement if not eating enough folate-rich foods

Delayed gastric emptying changes everything Tirzepatide slows stomach emptying significantly, especially during the first few weeks of treatment

"Comparative Analysis of GLP-1 Receptor Agonists in Weight Management." International Journal of Obesity Research, 2023

While it was initially developed for adults with type-2 diabetes, its effect in aiding weight loss has been widely noted in clinical studies